Baidu
map

BMC Public Health:纪立农等发现中国2型糖尿病患者达标率低

2013-07-24 BMC Public Health dxy

入组患者基线特征 中国成人中2型糖尿病(T2DM)的患病率增长迅速,但现有中国糖尿病管理和血糖控制状况的数据有限。为了评估口服降糖药(OADs)、胰高血糖素样肽-1(GLP-1)受体激动剂和胰岛素在中国多地区T2DM治疗中的疗效。来自北京大学纪立农教授及其团队进行了一项研究(Glycemic control among patients in China with type 2


入组患者基线特征

中国成人中2型糖尿病(T2DM)的患病率增长迅速,但现有中国糖尿病管理和血糖控制状况的数据有限。为了评估口服降糖药(OADs)、胰高血糖素样肽-1(GLP-1)受体激动剂和胰岛素在中国多地区T2DM治疗中的疗效。来自北京大学纪立农教授及其团队进行了一项研究(Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables),该研究发现不到三分之一的患者达到HbA1c<7.0%的目标。随着糖尿病病程延长,血糖达标率下降和胰岛素使用增加。该研究结果在线发表在2013年6月21日的《BMC公共卫生》(BMC Public Health)杂志上,该杂志影响因子为2.08。

该研究是一项在中国606家医院门诊患者中进行的多中心、横断面调查。在2011年4月至6月期间收集所有患者的数据。

该研究结果表明,共有238639例患者纳入该研究。合格的患者接受单用OADs(157212例[65.88%])、OADs联合胰岛素(80973例[33.93%])、或OADs联合GLP-1受体激动剂(454例[0.19%])治疗。OAD单药治疗组、OAD联合胰岛素组和OAD联合GLP-1受体激动剂组平均糖化血红蛋白(HbA1c)水平(+/-SD)分别为7.67%(+/-1.58%)、8.21%(+/-1.91%)、和7.80%(+/-1.76%)。三个组中,分别有34.63%、26.21%和36.21%的患者达到HbA1c<7.0%的目标。平均HbA1c和A1c<7.0%达标率与T2DM病程有关。

该研究发现,不到三分之一的患者达到HbA1c<7.0%的目标。随着糖尿病病程延长,血糖达标率下降和胰岛素使用增加。


Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC; Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables; BMC Public Health. 2013 Jun 21;13(1):602. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2013-09-19 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2014-01-21 bshuang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1860956, encodeId=4ecb1860956a9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Sep 19 00:13:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077962, encodeId=774720e796240, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue Jan 21 00:13:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974563, encodeId=a49519e456317, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Sep 26 01:13:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383135, encodeId=b72c138313536, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473726, encodeId=a29f14e372609, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621493, encodeId=c7271621493a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Jul 26 08:13:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]

相关资讯

JCEM:他汀类药物治疗降低糖尿病患者死亡风险

在糖尿病患者,他汀类药物常用于预防心血管疾病。然而,关于肥胖、适能和他汀类药物治疗与死亡率的相互关系的资料很少。为了评估在糖尿病患者中,他汀类药物治疗对体重指数(BMI)、心肺适能和全因死亡风险的影响,来自美国华盛顿退伍军人医疗中心的Eric Nylen教授及其团队进行了一项研究,该研究发现他汀类药物治疗降低糖尿病患者死亡风险。该研究结果在线发表在2013年6月19日的《临床内分泌代谢杂志》(Th

肾脏科与内分泌科专家建言糖尿病肾脏病诊疗

在2013年中国医师协会内分泌代谢科医师分会年会(2013.7.4-7.6,吉林长春)上,多位肾脏科和内分泌科专家一齐探讨糖尿病肾脏病诊疗。 首都医科大学附属北京安贞医院肾内科谌贻璞教授——定期检测GFR和白蛋白排泄率 糖尿病肾病(DKD)的早期诊断有赖于内分泌医生及时察觉患者的肾功能变化,建议糖尿病患者定期检测肾小球滤过率(GFR)和白蛋白排泄率。 糖尿病肾损害的治疗要根据疾病分期来决定。

CMAJ:糖尿病患者使用替米沙坦和缬沙坦并发心血管疾病风险较低

一项大规模的回顾性研究显示,相比于厄贝沙坦,糖尿病患者使用血管紧张素受体阻滞剂(ARBs) 替米沙坦(美压定,勃林格殷格翰)和缬沙坦时,发生大血管疾病的风险要明显降低。分析表明,使用替米沙坦(Telmisartan)和缬沙坦(Valsartan)可使心肌梗死、中风或心衰的住院风险分别降低15%和14%。而使用氯沙坦(Losartan)和坎地沙坦(Candesartan)糖尿病患者的心血管事件发生率

Diabetes Care:血中脂多糖(LPS)与糖尿病和肥胖密切相关

阐明肥胖和2型糖尿病的触发因素以改善患者治疗是极其重要的。已证明减肥手术能够预防甚至是治疗糖尿病,但是其作用机制未知。脂多糖(LPS)水平升高可预测糖尿病发生率,但是LPS的来源不甚清楚。为了评价血浆LPS对经减肥手术治疗的患者腹部肥胖和血糖控制的潜在影响,来自挪威奥斯陆大学医院传染病和微生物部的Troseid博士等人进行了一项研究,研究发现证明肠道细菌易位是肥胖和糖尿病的潜在触发因素,并表明减肥

Diabetes Care:髋部骨折后应激性高血糖增加急性心肌梗塞(AMI)风险

骨折与FBG的关系 为了研究髋部骨折后应激性高血糖之后的急性心肌梗塞(AMI)风险。来自北京首都医科大学北京安贞医院心内科的孟康教授及其团队进行了一项研究,研究发现,髋部骨折后应激性高血糖增加AMI风险。研究结果在线发表于2013年7月11日的美国《糖尿病治疗》(Diabetes Care)杂志上。 从2007年2月到2012年2月,研究人员对1,257名无糖尿病病史的

杨金奎:糖尿病患者应分层筛查视网膜病变

在2013年中国医师协会内分泌代谢科医师分会年会(2013.7.4-7.6,吉林长春)上,首都医科大学附属北京同仁医院杨金奎教授指出,糖尿病视网膜病变是成人最常见的致盲原因。强化降糖治疗可以防止或延迟糖尿病视网膜病变的发生。 除了血糖,其他一些因素也会增加视网膜病变风险,高血压是黄斑水肿的危险因素,也与增殖期视网膜病变的发生相关。亚临床甲状腺功能减低与威胁视力的视网膜病变相关,妊娠会加重糖尿病视

Baidu
map
Baidu
map
Baidu
map